Wegovy Cost in the UK: Pharmacy2U Pricing Guide

Pharmacy2U Wegovy cost is a common concern for patients exploring semaglutide 2.4 mg as a weight management option in the UK. Wegovy is a prescription-only GLP-1 receptor agonist available through private online pharmacy services, including Pharmacy2U, as well as through the NHS under strict eligibility criteria. Understanding the pricing structure, eligibility requirements, and how private costs compare to NHS provision can help patients make informed decisions. This article outlines current pricing considerations, who qualifies for treatment, and what alternatives exist for those who may not be eligible or cannot access Wegovy.

Wegovy Pricing at Pharmacy2U

Pharmacy2U supplies Wegovy on a private prescription basis, with costs varying by dosage strength and availability. Patients should check directly with the provider for current pricing, as supply constraints and demand can affect costs.

Wegovy (semaglutide 2.4 mg) is a prescription-only weight management medication available through Pharmacy2U and other online pharmacy services in the UK. The cost of Wegovy varies depending on whether you obtain it through an NHS prescription or via a private prescription service.

For private prescriptions Pharmacy2U charges £101.24–£276.24 (price-comparison listing, checked 12 August 2026) per month for Wegovy, depending on the dosage strength and current availability. Prices shown are indicative and may have changed. Always check directly with the provider for current pricing, as costs vary depending on the dose, plan, and any ongoing promotions. This price includes the medication itself. Patients should note that Wegovy treatment follows a gradual dose escalation schedule over several months, starting from 0.25 mg weekly and increasing to the maintenance dose of 2.4 mg weekly. The dose escalation can be delayed or maintained at a lower dose if side effects are not tolerated. For the exact schedule and guidance on managing intolerance, refer to the Wegovy UK Summary of Product Characteristics (SmPC).

Important considerations when purchasing Wegovy include:

• Supply constraints: Wegovy has experienced significant supply issues in the UK since its launch. Availability cannot be guaranteed, and waiting lists are common.

• Storage requirements: Wegovy pens must be stored in a refrigerator (2°C to 8°C) before first use. After first use, the pen can be kept at room temperature (below 30°C) or in the refrigerator for up to 6 weeks, in line with the UK SmPC.

• Prescription validity: A valid UK prescription from a registered prescriber is mandatory. Prescriptions may be issued by GMC-registered doctors or by appropriately trained independent prescribers registered with the GPhC or NMC.

• Regulatory checks: Before using any online pharmacy or prescribing service, verify they are registered with the relevant regulator. In England this means the General Pharmaceutical Council (GPhC) and Care Quality Commission (CQC). In Scotland the relevant body is Healthcare Improvement Scotland (HIS); in Wales, Healthcare Inspectorate Wales (HIW); and in Northern Ireland, the Regulation and Quality Improvement Authority (RQIA).

Patients should verify current pricing directly with pharmacy providers, as costs fluctuate based on supply, demand, and manufacturer pricing adjustments.

NHS vs Private Prescription Costs for Wegovy

NHS Wegovy access is highly restricted under NICE TA875 and limited to specialist services, while private prescriptions offer broader access at a significantly higher monthly cost. Patients in Scotland, Wales, and Northern Ireland pay no NHS prescription charge.

The cost difference between obtaining Wegovy through the NHS versus private prescription is substantial and represents a significant consideration for patients seeking this treatment.

NHS Prescription Costs

When Wegovy is prescribed through the NHS, patients in England pay the standard prescription charge of £9.90 per prescription item (from 1 May 2024). For those requiring ongoing treatment, a prescription prepayment certificate (PPC) offers considerable savings. Check the current PPC rates on the NHS Business Services Authority (NHSBSA) website, as charges are updated periodically. Patients in Scotland, Wales, and Northern Ireland receive free NHS prescriptions.^[3]

However, NHS availability of Wegovy is extremely limited. According to NICE Technology Appraisal 875 (TA875), NHS-funded Wegovy is restricted to patients who:

• Are treated within specialist weight management services

• Have a BMI of 35 kg/m² or above with at least one weight-related comorbidity, or a BMI of 30 kg/m² or above with at least one weight-related comorbidity (thresholds are reduced by 2.5 kg/m² for some ethnic groups, in line with NICE guidance)

• Can only receive treatment for a maximum of 2 years

A weight-related comorbidity is required at all BMI thresholds under TA875. Most NHS prescribing occurs within specialist tier 3 or 4 weight management services, with referral pathways varying across different Integrated Care Boards (ICBs). Meeting NICE criteria does not guarantee access: availability also depends on national commissioning decisions, local ICB pathways, and current stock levels.

Private Prescription Costs

Private prescriptions for Wegovy through Pharmacy2U typically cost £101.24–£276.24 per month, depending on dosage strength. Prices shown are indicative and may have changed. Always check directly with the provider for current pricing, as costs vary depending on the dose, plan, and any ongoing promotions.

Key differences include:

• Accessibility: Private prescriptions may offer faster access without NHS waiting lists, though availability remains subject to national supply constraints.

• Eligibility criteria: Private services should follow the licensed indication criteria, though NHS funding has additional restrictions through NICE guidance.

• Ongoing monitoring: NHS services typically provide comprehensive multidisciplinary support including dietetic input, whereas private services may charge separately for follow-up consultations.

Patients should discuss both NHS and private options with their GP to determine the most appropriate pathway. GPs generally cannot convert private prescriptions to NHS prescriptions unless the patient meets local NHS eligibility criteria and follows established referral pathways.

Eligibility Criteria for Wegovy Treatment

Wegovy is licensed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with a weight-related comorbidity such as type 2 diabetes or hypertension. NHS funding requires additional criteria including treatment within specialist services and a maximum duration of 2 years.

Wegovy is not suitable for everyone seeking weight loss. The criteria for prescribing include both the licensed indication (MHRA marketing authorisation) and, for NHS-funded treatment, additional NICE guidance restrictions.

Licensed Indication (MHRA)

Wegovy is licensed for weight management in adults with:

• Body Mass Index (BMI) of 30 kg/m² or above (obesity), or

• BMI of 27 kg/m² or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease

• Age 18 years or older

• As an adjunct to a reduced-calorie diet and increased physical activity

NHS Funding Criteria (NICE TA875)

For NHS-funded treatment, additional restrictions apply:

• Treatment must be provided by specialist weight management services

• At least one weight-related comorbidity is required at all BMI thresholds

• BMI thresholds are reduced by 2.5 kg/m² for some ethnic groups, in line with NICE guidance

• Maximum treatment duration of 2 years

Contraindications

Wegovy must not be prescribed to patients with:

• Pregnancy (effective contraception should be used during treatment, and semaglutide should be discontinued at least 2 months before a planned pregnancy)^[1]

• Hypersensitivity to semaglutide or any excipients

Cautions and Special Warnings

The following are listed as cautions or warnings in the UK SmPC for Wegovy. Patients should discuss their full medical history with their prescriber:

• Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2): the UK SmPC advises that patients with these conditions should be counselled about symptoms and that Wegovy should be used with caution

• Diabetic retinopathy (particularly in patients with diabetes using insulin)

• History of pancreatitis

• Gallbladder disease

• Severe renal impairment: no routine dose adjustment is required, but patients should be monitored carefully due to the risk of dehydration from gastrointestinal side effects

• Breastfeeding (not recommended)

Assessment Process

Before prescribing Wegovy, clinicians should:

• Conduct a comprehensive medical history and physical examination

• Assess cardiovascular risk factors and comorbidities

• Screen for eating disorders

• Discuss realistic weight loss expectations: in the STEP clinical trials, participants lost on average around 15% of body weight over 68 weeks, though individual results vary considerably

• Establish a plan for dietary modification and physical activity alongside medication

Treatment continuation should be assessed at approximately 16 weeks (after 12 weeks at the 1.7 mg dose), in line with the UK SmPC. If a patient has not achieved at least 5% weight loss by this point, discontinuation should be considered, as further benefit is unlikely. Patients should seek urgent medical attention if they experience severe, persistent abdominal pain, which may indicate pancreatitis or gallbladder disease.

Patients should report any suspected side effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Alternative Weight Loss Medications and Costs

Alternatives to Wegovy in the UK include orlistat, Saxenda (liraglutide 3.0 mg), Mysimba (naltrexone/bupropion), and tirzepatide (Mounjaro), each with different mechanisms, costs, and eligibility criteria. Lifestyle modification and NHS-funded programmes remain the cornerstone of weight management.

For patients who do not meet eligibility criteria for Wegovy, cannot afford the medication, or experience intolerable side effects, several alternative weight management medications are available in the UK, each with different mechanisms of action and cost profiles.

Orlistat (Xenical/Alli)

Orlistat is a lipase inhibitor that reduces dietary fat absorption by approximately 30%. It is available both on prescription (120 mg) and over-the-counter (60 mg as Alli). NHS prescription costs are the standard prescription charge per item, whilst private prescription costs vary by provider. Prices shown are indicative and may have changed. Always check directly with the provider for current pricing. Orlistat produces modest average weight loss over 12 months; refer to NICE Clinical Knowledge Summary (CKS) on obesity or the BNF for current efficacy data. Common side effects include oily stools, faecal urgency, and flatulence, particularly when consuming high-fat meals.

Saxenda (Liraglutide 3.0 mg)

Saxenda is another GLP-1 receptor agonist, similar to Wegovy but requiring daily rather than weekly injections. Private prescription costs vary by provider. Prices shown are indicative and may have changed. Always check directly with the provider for current pricing. Clinical evidence indicates that Saxenda typically produces less weight loss than Wegovy; refer to the respective UK SmPCs and NICE guidance for comparative efficacy data. Eligibility criteria are similar to those for Wegovy.

Mysimba (Naltrexone/Bupropion)

Mysimba combines an opioid antagonist with an antidepressant to reduce appetite and food cravings. Private costs vary by provider. Prices shown are indicative and may have changed. Always check directly with the provider for current pricing. It is contraindicated in patients with uncontrolled hypertension, seizure disorders, current or previous eating disorders, bipolar disorder, abrupt discontinuation of alcohol or sedatives, and in patients using chronic opioids. For current efficacy data, refer to the Mysimba UK SmPC or BNF.

Tirzepatide (Mounjaro)

Tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist licensed in the UK for both type 2 diabetes management and chronic weight management. Patients should discuss with their healthcare provider whether this might be an appropriate option, taking into account their individual circumstances and the relevant licensed indications.

Non-Pharmacological Alternatives

Patients should be reminded that lifestyle modification remains the cornerstone of weight management. NHS-funded programmes such as the NHS Digital Weight Management Programme offer structured support at no cost. For those with a BMI of 40 kg/m² or above (or 35 kg/m² or above with comorbidities), bariatric surgery may be appropriate and is available through the NHS following specialist assessment.

Scientific References

1. Wegovy 0.25 mg, FlexTouch solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC).
2. Semaglutide for managing overweight and obesity. Technology Appraisal Guidance [TA875].
3. NHS prescription charges from 1 May 2024.
4. Wegovy - European Public Assessment Report (EPAR).
5. Once-Weekly Semaglutide in Adults with Overweight or Obesity.
6. Wegovy (Semaglutide) Weight Loss Injections.

Frequently Asked Questions